Evaluation of the Levels of Pain and Discomfort and Periodontal Status Between Two Acceleration Methods of Upper Anterior Teeth Retraction

Sponsor
Damascus University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05656898
Collaborator
(none)
57
1
3
27.1
2.1

Study Details

Study Description

Brief Summary

57 patients will be treated by extraction of maxillary first premolars by applying mini-screws between the maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). They will be divided randomly into three groups in this trial. The prolonged duration of the treatment period can cause many side effects such as white spots, caries, periodontal diseases, and pain and discomfort. So many efforts have been made to reduce the treatment time. Many procedures have been introduced to accelerate orthodontic tooth movement, which can category as surgical or non-surgical. Piezocision is a minimally invasive surgical method for accelerating orthodontic tooth movement and shortening treatment time. Low-level laser therapy (LLLT) is one of the physical acceleration methods that have contributed to decreasing treatment time.

Condition or Disease Intervention/Treatment Phase
  • Device: Piezocision+GaALAs diode laser
  • Device: Piezocision
  • Device: Orthodontic fixed appliance
N/A

Detailed Description

Closed nickel-titanium coil springs applying 250 g of force per side will be used for retraction of the maxillary anterior teeth.

The en-masse retraction will be obtained with two nickel-titanium coil springs placed between the mini-implants and the soldered hooks in a direction approximately parallel to the occlusal plane, a force of 250 g will be applied on each side to perform en-masse retraction. The retraction will be stopped when a Class I canine relation is achieved and a good incisor relation is obtained or spaces lateral to canines are closed.

Regarding the Piezocision, vertical soft-tissue incisions will be made on the buccal and palatal gingiva. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla. Then a piezosurgery knife will be inserted to perform the cortical alveolar incisions with 3-mm in-depth and 8 mm in length. No suturing will be needed.

Regarding the piezocision with the later application of low-level laser therapy (LLLT):

After seven weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\point) 10 seconds per point will be applied on each tooth of the six maxillary anterior teeth according to this protocol: the root will be divided theoretically into 2 halves; gingival and cervical, and the laser will be applied in the centre of each half from both buccal and palatal sides which means 4 application points and total energy of 16 Joules per tooth. The LLLT will be applied 5 times in the first month of en masse retraction. After that, the irradiation will be repeated every two weeks, until the class, I canine relationship will be achieved and/or spaces lateral to incisors were closed

Study Design

Study Type:
Interventional
Anticipated Enrollment :
57 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Comparison Between the Flapless Corticotomy Enhanced by the Later Application of Low-intensity Laser Therapy on Patient-centred Outcomes and Periodontal Health in Patients Undergoing en Masse Retraction of Upper Anterior Teeth
Actual Study Start Date :
Feb 9, 2021
Actual Primary Completion Date :
Dec 2, 2022
Anticipated Study Completion Date :
May 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Piezosurgery pulse Low-level laser therapy

Piezocision will be applied in this group of patients using a piezosurgery knife and after 6 weeks of initial retraction, low-level laser therapy will be applied in this group of patients using a diode laser device.

Device: Piezocision+GaALAs diode laser
After seven weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\point) 10 seconds per point will be applied on each tooth of the six maxillary anterior teeth .

Experimental: Piezosurgery

Piezocision will be applied in this group of patients using a piezosurgery knife.

Device: Piezocision
Vertical soft-tissue incisions will be made on the buccal and palatal gingiva. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.

Active Comparator: Traditional treatment

En masse retraction in this group will be performed in a conventional method.

Device: Orthodontic fixed appliance
Closed nickel-titanium coil springs applying 250 g of force per side will be used for retraction of the maxillary anterior teeth.

Outcome Measures

Primary Outcome Measures

  1. Change in the levels of pain during the first month of treatment assessed by the VAS [Time 1: 12 hours, Time 2: Day 1, Time 3: Day 3, Time 4: Day 7, Time 5: Day 14, following the commencement of the retraction.]

    Assessment will be performed using questionnaires via the Visual Analog scale (VAS). The Visual Analog Scale is a 100 mm horizontal line with two focal points at its beginning and end (0: no pain - 100: the worst pain).

  2. Change in the levels of pain during the third month of treatment assessed by the VAS [Time 1: 12 hours, Time 2: Day 1, Time 3: Day 3, Time 4: Day 7, Time 5: Day 14, following the commencement of the retraction.]

    Assessment will be performed using questionnaires via the Visual Analog Scale (VAS). The Visual Analog Scale is a 100 mm horizontal line with two focal points at its beginning and end (0: no pain - 100: the worst pain).

  3. Change in the levels of discomfort during the first month of treatment assessed by the VAS [Time 1: 12 hours, Time 2: Day 1, Time 3: Day 3, Time 4: Day 7, Time 5: Day 14, following the commencement of the retraction.]

    Assessment will be performed using questionnaires via the Visual Analog scale (VAS). The Visual Analog Scale is a 100 mm horizontal line with two focal points at its beginning and end (0: no pain - 100: the worst pain).

  4. Change in the levels of discomfort during the third month of treatment assessed by the VAS [Time 1: 12 hours, Time 2: Day 1, Time 3: Day 3, Time 4: Day 7, Time 5: Day 14, following the commencement of the retraction.]

    Assessment will be performed using questionnaires via the Visual Analog scale (VAS). The Visual Analog Scale is a 100 mm horizontal line with two focal points at its beginning and end (0: no pain - 100: the worst pain).

  5. Change in the levels of swelling during the first month of treatment assessed by the VAS [Time 1: 12 hours, Time 2: Day 1, Time 3: Day 3, Time 4: Day 7, Time 5: Day 14, following the commencement of the retraction.]

    Assessment will be performed using questionnaires via the Visual Analog scale (VAS). The Visual Analog Scale is a 100 mm horizontal line with two focal points at its beginning and end (0: no pain - 100: the worst pain).

  6. Change in the levels of swelling during the third month of treatment assessed by the VAS [Time 1: 12 hours, Time 2: Day 1, Time 3: Day 3, Time 4: Day 7, Time 5: Day 14, following the commencement of the retraction.]

    Assessment will be performed using questionnaires via the Visual Analog scale (VAS). The Visual Analog Scale is a 100 mm horizontal line with two focal points at its beginning and end (0: no pain - 100: the worst pain).

  7. Change in the levels of eating difficulty during the first month of treatment assessed by the VAS [Time 1: 12 hours, Time 2: Day 1, Time 3: Day 3, Time 4: Day 7, Time 5: Day 14, following the commencement of the retraction.]

    Assessment will be performed using questionnaires via the Visual Analog scale (VAS). The Visual Analog Scale is a 100 mm horizontal line with two focal points at its beginning and end (0: no pain - 100: the worst pain).

  8. Change in the levels of eating difficulty during the third month of treatment assessed by the VAS [Time 1: 12 hours, Time 2: Day 1, Time 3: Day 3, Time 4: Day 7, Time 5: Day 14, following the commencement of the retraction.]

    Assessment will be performed using questionnaires via the Visual Analog scale (VAS). The Visual Analog Scale is a 100 mm horizontal line with two focal points at its beginning and end (0: no pain - 100: the worst pain).

  9. Change in the levels of satisfaction assessed by the VAS [These levels will be assessed only at day 14 of month 3 following the commencement of the retraction.]

    Assessment will be performed using questionnaires via the Visual Analog scale (VAS). The Visual Analog Scale is a 100 mm horizontal line with two focal points at its beginning and end (0: no pain - 100: the worst pain).

Secondary Outcome Measures

  1. The change in the plaque index [Time 0: immediately before applying the fixed appliance; Time 1: Day 1 before the commencement of the retraction phase; Time 2: at the end of the retraction phase]

    Assessment will be achieved using a gingival probe according to Silness and Loe (1964) to assess oral hygiene status in enrolled patients. A. (0) = No plaque. B. (1) = A film of plaque stuck to the free gingival margin and adjacent area of the tooth. C. (2) = Moderate accretion of soft deposits on the tooth and gingival margin or within the gingival pocket. D. (3) = Abundance of soft material on the tooth and gingival margin and/or within the gingival pocket.

  2. The change in the gingival index [Time 0: immediately before applying the fixed appliance; Time 1: Day 1 before the commencement of the retraction phase; Time 2: at the end of the retraction phase]

    Assessment will be achieved using a gingival probe according to Silness and Loe (1964) to assess the status of the gingival tissues around the upper teeth (from the 2nd premolar to the contralateral 2nd premolar). A. (0) = Normal gingiva. B. (1) = Mild inflammation: minor colour change, slight oedema. No bleeding on probing. C. (2) = Moderate inflammation: redness, oedema and glazing and bleeding on probing. D. (3) = Sever inflammation: marked redness and oedema, ulceration, and tendency to spontaneous bleeding.

  3. The change in the bleeding index [Time 0: immediately before applying the fixed appliance; Time 1: Day 1 before the commencement of the retraction phase; Time 2: at the end of the retraction phase]

    Assessment will be achieved using a gingival probe according to Muhlemann (1977) to assess the status of periodontal tissues around the upper teeth (from the 2nd premolar to the contralateral 2nd premolar). A. (0) = No bleeding. B. (1) = A single discreet bleeding point appears. C. (2) = Several isolated bleeding points or a single fine line of blood appears. D. (3) = The interdental triangle fills with blood shortly after probing. E. (4) = Profuse

Eligibility Criteria

Criteria

Ages Eligible for Study:
17 Years to 28 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Adult healthy patients, Male and female, Age range: 17-28 years.

  2. Class II Division 1 malocclusion :

  • Mild/moderate skeletal Class II (sagittal discrepancy angle ≤7)

  • Overjet ≤10

  • Normal or excessive facial height (Clinically and then cephalometrically assessed using these three angles: mandibular/cranial base angle, maxillary/mandibular plane angle, and facial axis angle)

  • Mild to moderate crowding ≤ 4

  1. Permanent occlusion.

  2. Existence of all the upper teeth (except third molars).

  3. Good oral and periodontal health:

  • Probing depth < 4 mm

  • No radiographic evidence of bone loss.

  • Gingival index ≤ 1

  • Plaque index ≤ 1

Exclusion Criteria:
  1. Medical problems that affect tooth movement (corticosteroid, nonsteroidal anti-inflammatory drugs (NSAIDs), …)

  2. Presence of primary teeth in the maxillary arch

  3. Missing permanent maxillary teeth (except third molars).

  4. Poor oral hygiene or Current periodontal disease:

  • Probing depth ≥ 4 mm

  • radiographic evidence of bone loss

  • Gingival index > 1

  • Plaque index > 1

  1. The patient had previous orthodontic treatment

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Damascus Damascus Syrian Arab Republic

Sponsors and Collaborators

  • Damascus University

Investigators

  • Principal Investigator: Mudar Mohammad Mousa, DDS, Department of orthodontics, Damascus University, Syria
  • Study Director: Mohammad Y. Hajeer, DDS,MSc,PhD, Department of orthodontics, Damascus University, Syria

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Damascus University
ClinicalTrials.gov Identifier:
NCT05656898
Other Study ID Numbers:
  • UDDS-Ortho-16-2021
First Posted:
Dec 19, 2022
Last Update Posted:
Dec 19, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 19, 2022